Novartis heart failure drug's trial changed due to Alzheimer's disease concerns; Gilead appears to be stashing profits overseas; BMS releases high cure rate data for its investigational HCV combination.
The organization plans to publish a scientific and a lay abstract detailing study findings
Potential patients are expected to be newly diagnosed diabetes patients as opposed to Lantus switchers.
Some IDNs are centralizing decisionmaking at the corporate level and other hospitals are limiting on-site access to sales reps.
A report by the New York Times, citing a lack of an advisory committee for Vyvanse and illegal marketing lawsuits resolved last year, expressed concerns that the drug for binge-eating disorder will be overprescribed.
Industry rare disease awareness efforts included a pipeline overview at Pfizer as well as BI's efforts to draw attention to IPF.
The EU will have access to the new medication in May.
The survey shows the use of stronger-than-morphine painkillers has jumped.
Sanofi's Lantus predecessor nabs approval; Pharmacyclics reportedly vets acquisition offers; FDA biosimilar hearing is postponed.
Millennials and baby boomers have a lot of common: a desire for technology that supports health priorities.
Smartphones drove network traffic.
The over-the-counter weight-loss drug Alli saw a return to drugstores this week after a year hiatus.
J&J loses another Risperdal case; Pfizer slashes jobs at research center; Actavis challenges ulcerative colitis drug's patent.
The global cancer market is expected to reach $111 billion by 2020, according to new market research, with immunotherapies—particularly in lung cancer—expected to drive growth.
Assemblyman David Chiu's bill would publish a drug's R&D and related costs.
Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.
FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.
The drugmaker wants to put the drug through additional liver-impact tests.
A MedPanel survey indicates doctors have not changed their business practices since the Open Payments database went live.
The Trustworthy Accountability of National Advertisers launched its naming-names initiative in November, but the list is empty.
Valeant grabs Salix for $10.4 billion, BMS inks to collaborations deals and Pfizer lines up to have the first treatment for a rare lung disease.
23andMe is back in the DTC game; Sanofi has named its new CEO; drug companies are contemplating a pay-for-performance sales model.
Americans may be taking anti-cholesterol medications, but it doesn't mean they are aware of their impact.
An NIH study shows possible limit to Lucentis's appeal.
The Healthcare Businesswomen's Association named Denice Torres, president of J&J's McNeil Consumer Healthcare, as its 26th Woman of the Year.
Lilly delays Phase-III cholesterol drug results; PatientsLikeMe and Walgreens team up for "drug reaction reviews"; Roche skin-cancer drug receives Priority Review.
Celgene's cancer drug is now approved for newly diagnosed patients.
Scientist Cori Bargmann's Twitter history makes the nomination a bit of a surprise.
Researchers find repeat marketing offenders in the UK and Sweden, Actavis plans to take Allergan's name and Sanofi enters an auto-immune disease collaboration.
A small physician survey shows doctors think their patients have higher adherence rates than the norm.
CVS health execs write that cost of long-term specialty medications, not short-timers like Sovaldi, are a major worry.
A New Jersey District Court ruled that the Pulmicort Respules patent is invalid, opening the door for Actavis to launch a generic version of the billion-dollar asthma drug.
Bayer exec may be Sanofi's new CEO, GSK gets a new North American Pharma lead, and Pfizer sends painkiller ALO-02 to the FDA.
FDA approves Eisai's thryoid cancer drug two months early, Gilead and Germany agree to a Sovaldi price cut, and Valeant looks set to make a bid for Salix.
AARP researchers found that the celebrity's decision to go public triggered a surge in genetic screening.
Pfizer's academic research arm will work together with the Alzheimer's Drug Discovery Foundation to jointly invest in scientific research to identify clinical candidates for testing.
Hospira is planning a Lucentis biosimilar, Roche is expanding is cancer diagnostics portfolio, and cholesterol may not be as bad as originally thought (but smoking is worse than ever).
The initial push includes a behind-the-scenes Tumblr and broadcast plans are being finalized.
The Paris-based drugmaker has axed 100 oncology and global R&D employees as part of a reorganization effort.
BMS loses breakthrough therapy status, Gilead's pricing comes under fire in Europe, and pharma fights Italy's off-label Avastin use.
The list of objections by the Office of Prescription Drug Promotion, which oversees medical advertising, is a familiar one, and includes concerns such as claims that go beyond the approved indication.
A Merck survey that indicated distaste for British Columbia's decision to boot Januvia from the formulary has stirred up debate over bias.
FDA's latest guidance says it is ok to reduce the amount of risk information in print ads, Google amplifies the health information it will serve up with searches and HBO's John Oliver takes on pharmaceutical marketing.
Achillion's experimental HCV drug cleared the virus in six weeks when combined with Gilead's Sovaldi; Sanofi will replace a third of its sales managers; GSK shutters Montana vaccine R&D.
Genentech Parkinson med encounters preliminary safety issues; Cigna gives Gilead's Harvoni preferred status over AbbVie's Viekira Pak; Valeant proposes $400 million bid to buy bankrupt Dendreon.
Pfizer said the $17-billion decision to acquire Hospira will not affect the timeline of its divide-or-stay-whole decision.
A survey showed patients are not really clear on what causes cancer.
FDA commissioner Margaret Hamburg has stepped down; Pfizer acquires Hospira for $15.2 billion, AstraZeneca buys Actavis's branded respiratory business.
The drugmaker announced in its earnings call Wednesday that the FDA has rescinded the company's Breakthrough Therapy designation, which could delay Merck's HCV doublet therapy launch from early to mid-2016.
The FDA approved the breast cancer drug Tuesday afternoon. Estimated peak sales: $3.8 billion.
The original required 26 bits of information and seven attachments.
One in three adults would rather not take a pill and have a shorter life span; Pfizer's next-gen breast-cancer drug nabs an early approval; Amgen's Humira biosimilar demonstrates clinical equivalence.
Measles outbreak news aside, doctors need help identifying illnesses vaccines have made uncommon.
Researchers say the golden-age of profits appears to be over, and the industry may need help funding innovation.
The reason: higher prices and more services.
The health minister is threatening price-related legislation.
Shire's ADHD treatment Vyvanse won a label expansion into treating moderate-to-severe binge-eating disorder (BED) Friday. One analyst says that disease awareness and detailing efforts are crucial to the drug's commercial plans in the category.
The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.
Pfizer ends spinal muscular atrophy collaboration; abuse-deterrent Zohydro scores approval; measles outbreak at Disneyland linked to 36 cases.
Obama's precision medicine initiative looks set for bipartisan support, Valeant has offered $296 million to buy Dendreon and researchers say Roche's Tamiflu works.
Researchers found that 25% of ACA-compliant plans put HIV drugs in the highest formulary tier.
Alexion's CEO Leonard Bell is retiring, and TripAdvisor's Christine Peterson has joined Treato.
The label will now include Waldenstrom's macroglubulinemia.
Former FDA chief tells court J&J knew of Risperdal risk, pay-for-delay deals get new court criteria, lawmakers may declare pharmacists healthcare providers.
MS drugmaker Biogen Idec drafted Tyler Campbell, son of NFL Hall of Fame running back Earl Campbell, and former Dallas Mavericks point guard Chris Wright to help inspire sufferers of multiple sclerosis.
Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.
Doximity professional network now includes financial data; Pfizer settles class-action lawsuit; researchers hope to use temporary tattoos to identify glucose levels.
Hysingla ER is ready for the marketplace, just two months after FDA approval.
CEO Ian Read told investors the company has cash to make a deal, but there is no urgent need.
Biogen Idec handed out 250 Fitbits last year to better understand how MS affects patients' mobility, and how its medications hinder disease progression.
AstraZeneca's Nexium now has generic competition, toxicity worries researchers about new cancer approaches and a former Pfizer exec will now lead an e-cigarette company.
The FDA approved NPS Pharmaceuticals's rare-disease drug Friday. The company, which Shire shelled out $5.2 billion to buy, expects it to hit the market during the second-quarter.
The drugmakers have filed alirocumab with the FDA, closing the gap between its candidate and Amgen's evolucumab.
FDA has approved Novartis's Bexsero after approving Pfizer's Trumemba this past October.
Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.
Actavis acquires Auden Mckenzie for $459 million; Sanofi/Regeneron's PCSK9 inhibitor could be first to market; Gilead strikes a deal for Harvoni and Sovaldi with four German health insurers.
Brent Saunders, the mind behind the $66 billion acquisition of Allergan, which elevated Actavis to the tenth-largest drugmaker in the world, tells Forbes that growth through acquisition is not simply a short-term tactic but part of a long-term strategy.
The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.
Tina Fascetti is the mid-sized agency's new Chief Creative Officer. CEO Matt Brown (and ICC Lowe alum) tells MM&M the new Guidemark is just getting started.
Takeda COO Weber refuses Sanofi CEO post; J&J seeks $7.2 billion from Boston Scientific over 10-year old-Guidant acquisition; UCB submits epilepsy drug for US and EU approval.
A novel psoriasis treatment approved today, which demonstrated superiority to TNF inhibitors, could unseat entrenched competitors like Amgen's Enbrel and J&J's Stelara.
The hepatitis C medication will be on the US dustheap, but Merck expects to file a new drug with the FDA later this year.
Marketers may want to dust off plans to create NP-centric materials.
Novartis's Sandoz will kickstart its marketing plans as it awaits FDA's decision to approve the first biosimilar in the US.
Despite growth, some disappointment lurks in the numbers -- possibly for hepatitis C medication Olysio.
The ruling stalls generics until at least September.
FDA draws fine line between health and wellness apps; Colorado gives biosimilar swap law another look; ZMapp is set to start human trials of its Ebola vaccine.
CMS head Marilyn Tavenner has resigned; Depomed acquires Nucynta pain pill from J&J; Merck's innovation lead leaves for insurer.
Boehringer Ingelheim announced Thursday that it may sell its Roxane Labs generics business, which Bloomberg says may be worth up to $2.3 billion.
Swedish researchers found rheumatoid arthritis patients tend to drop their first anti-TNF treatment.
A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.
Clinical trials indicate the CETP works for specific genetic profiles.
Pharma ad budgets are growing, says IPG; Medical device tax debate rages on; Pfizer has PCSK9 pill in the works.
The FDA is looking into whether abbreviated risk information is a good idea for DTC.
Prime Therapeutics gives Gilead's Harvoni and AbbVie's Viekira Pak preferred formulary status; Novartis and Qualcomm team up for new investment firm; UK cost watchdog axes cancer drug coverage.
Pfizer, through the Better Business Bureau's National Advertising Division, disputes that Novartis's Theraflu 'starts to work in the body in 5 minutes.'
News flowing from Bristol-Myers Squibb and Merck show the two companies may fight for elbow room among lung cancer patients with drugs that have already started building credibility in other indications.
HHS says the government and Seattle Seahawks discussed the PSA soon after the 2014 Superbowl win.
The $509-million agreement gives J&J rights to AC Immune's experimental anti-Tau vaccine.
BMS halts cancer drug trial over positive Phase-III results; Shire has acquired NPS Pharmaceuticals for $5.2 billion; 23andMe expands Pfizer agreement.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.